Antigen-Specific Proteins Targeting SARS-CoV-2 RBD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current approaches to prevent SARS-COV-2 infection, such as monoclonal antibodies targeting the Spike glycoprotein, may be ineffective against resistant virus mutations, necessitating the development of cocktails of antibodies that can bind specifically to the RBD domain of the Spike protein to interfere with the ACE2 receptor interaction.
Innovation Solution
The isolation of antigen-specific proteins using phage display technology, specifically targeting the RBD domain of the Spike protein, which are capable of binding in the low nanomolar range and neutralizing the virus by interfering with the Spike protein's interaction with the ACE2 receptor, either as purified proteins or expressed on cells, and their use in therapeutic and diagnostic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies targeting the Spike glycoprotein are used to prevent SARS-COV-2 infection, then virus entry is blocked, but effectiveness is reduced against resistant virus mutations
Solution Approach 1:
The invention divides the antibody response into multiple specific components by isolating and characterizing distinct monoclonal antibodies (such as D3, F12, S96, AC2) that target different epitopes on the RBD domain. This segmentation allows each antibody to recognize specific viral structures, improving reliability against mutations while maintaining adaptability through diversity in binding specificity.
Solution Approach 2:
The invention changes the binding parameters of the antibodies by achieving low nanomolar affinity (e.g., Kd values in the range of 10^-9 M) through phage display selection. This parameter optimization enhances the antibodies' ability to bind to the RBD domain with high specificity, thereby improving effectiveness against resistant mutations while maintaining versatility across different viral strains.
2Measurement precision
If phage display technology is used to isolate human anti-Spike-RBD mAbs, then binding specificity to RBD domain is achieved, but complexity of isolation process increases
Solution Approach 1:
The invention uses phage display technology as an intermediary system to isolate human anti-Spike-RBD monoclonal antibodies. The phage particles serve as vectors that display antibody fragments, enabling selective binding to the RBD domain. This intermediary approach achieves high binding specificity while managing the complexity of the isolation process through a systematic, multi-step protocol involving phage library construction, panning, and screening.
3Reliability
If cocktails of mAbs are generated to block virus entry, then resistance to mutations is improved, but complexity of therapeutic formulation increases
Solution Approach 1:
The invention merges multiple monoclonal antibodies (D3, F12, S96, AC2) into coordinated cocktails that work synergistically to block virus entry. Each antibody in the cocktail targets different epitopes on the RBD domain, creating a comprehensive blockade that is difficult for the virus to overcome through mutations. This merging approach improves reliability while managing formulation complexity through standardized combination protocols.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These antigen-specific proteins effectively neutralize SARS-COV-2 infection and its variants, offering a potential therapeutic and diagnostic solution by specifically binding to the RBD domain and blocking the virus's entry into cells, while also being effective against different viral strains and variants.
Implementation Method 1
specifically binding to RBD domain and interfering in the interaction of Spike protein with ACE2 receptor
Implementation Method 2
having neutralizing activity for infection by SARS-COV2 virus and its variants
Data Source
AI summary
The invention concerns antigen specific proteins, in particular antibodies or fragments thereof, specifically binding to RBD domain and interfering in the interaction of Spike protein with ACE2 receptor, said antigen specific proteins having neutralizing activity for infection of SARS-COV2 virus and its derived variants.